Chinese researchers report a pig kidney transplant and a first-step liver experiment
A Chinese patient is the third person in world known to be living with a gene-edited pig kidney. And the same research team also reported an experiment implanting a pig liver into a brain-dead person.
Scientists are genetically altering pigs so their organs are more humanlike in hopes of alleviating a transplant shortage. Two initial xenotransplants in the U.S. — two pig hearts and two pig kidneys – were short-lived. But two additional pig kidney recipients so far are thriving – an Alabama woman transplanted in November and a New Hampshire man transplanted in January. A U.S. clinical trial is about to begin.
Nearly three weeks after the kidney surgery the Chinese patient "is very well' and the pig kidney likewise is functioning very well, Dr. Lin Wang of Xijing Hospital of the Fourth Military Medical University in Xi'an told reporters in a briefing this week.
Wang, part of the hospital's xenotransplant team, said the kidney recipient remains in the hospital for testing. Chinese media have reported she is a 69-year-old woman diagnosed with kidney failure eight years ago.
But Wang pointed to a potential next step in xenotransplantation — learning to transplant pig livers. His team reported Wednesday in the journal Nature that a pig liver transplanted into a brain-dead person survived for 10 days, with no early signs of rejection. He said the pig liver produced bile and albumin — important for basic organ function — although not as much as human livers do.
The liver is a complex challenge because of its varied jobs, including removing waste, breaking down nutrients and medicines, fighting infection, storing iron and regulating blood clotting.
'We do find that it could function a little bit in a human being,' Wang said. He speculated that would be enough to help support a failing human liver.
In the U.S. last year, surgeons at the University of Pennsylvania attempted that sort of 'bridge' support by externally attaching a pig liver to a brain-dead human body to filter blood, much like dialysis for failing kidneys. U.S. pig developer eGenesis is studying that approach.
In China, Wang's team didn't remove the deceased person's own liver, instead implanting the pig liver near it.
That 'clouds the picture,' said Dr. Parsia Vagefi, a liver transplant surgeon at UT Southwestern Medical Center who wasn't involved with the work. 'It's hopefully a first step but it's still, a lot like any good research, more questions than answers.'
Wang said his team later replaced the human liver of another brain-dead person with a pig liver and is analyzing the outcome.
According to media reports, another Chinese hospital last year transplanted a pig liver into a living patient after a piece of his own cancerous liver was removed but it's unclear how that experiment turned out.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
8 hours ago
- San Francisco Chronicle
New malaria drug for babies offers hope to health workers in Uganda
KAMPALA, Uganda (AP) — Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a miscarriage later attributed to untreated malaria in her. The Ugandan farmer said recently that she regretted the loss of what would have been her second child 'because I didn't discover malaria and treat it early.' Variations of such cases are commonly reported by Ugandan health workers who witness stillbirths or feverish babies that die within days from undiagnosed malaria. The deaths are part of a wider death toll tied to the mosquito-borne disease, the deadliest across Africa, but one easily treated in adults who seek timely medical care. Until recently, a major gap in malaria treatment was how to care for newborns and infants infected with malaria who weren't strong enough to receive regular medication. That changed last month when Swiss medical regulators approved medicine from the Basel-based pharmaceutical company Novartis for babies weighing between 2 and 5 kilograms (nearly 4½ to 11 pounds). Swissmedic said the treatment, a sweet-tasting tablet that disperses into a syrup when dropped into water, was approved in coordination with the World Health Organization under a fast-track authorization process to help developing countries access much-needed treatment. Africa's 1.5 billion people accounted for 95% of an estimated 597,000 malaria deaths worldwide in 2023, according to the WHO. More than three-quarters of those deaths were among children. In Uganda, an east African country of 45 million people, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023. Many were children younger than 5 and pregnant women, according to WHO. Nigeria, Congo and Uganda — in that order — are the African countries most burdened by malaria, a parasitic disease transmitted to humans through the bites of infected mosquitoes that thrive and breed in stagnant water. The drug approved by Swiss authorities, known as Coartem Baby in some countries and Riamet Baby in others, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including for older children. Before Coartem Baby, antimalarial drugs designed for older children were administered to small infants with careful adjustments to avoid overdose or toxicity. Ugandan authorities, who have been working to update clinical guidelines for treating malaria, say the new drug will be rolled out as soon as possible. It is not yet available in public hospitals. The development of Coartem Baby has given hope to many, with local health workers and others saying the medicine will save the lives of many infants. Ronald Serufusa, the top malaria official for the district of Wakiso, which shares a border with the Ugandan capital of Kampala, said he believes Coartem Baby will be available 'very, very soon' and that one priority is sensitizing the people adhering to treatment. Some private pharmacies already have access to Coartem Baby, 'flavored with orange or mango' to make it palatable for infants, he said. During the so-called malaria season, which coincides with rainy periods twice a year, long lines of sick patients grow outside government-run health centers across Uganda. Many are often women with babies strapped to their backs. Health workers now are trained to understand that 'malaria can be implicated among newborns,' even when other dangerous conditions like sepsis are present, Serufusa said. 'If they don't expand their investigations to also suspect malaria, then it goes unnoticed,' he said, speaking of health workers treating babies. The Malaria Consortium, a global nonprofit based in London, in a statement described the approval of Coartem Baby as 'a major leap forward for saving the lives of young children in countries affected by malaria.' In addition to Uganda, the drug will be rolled out in Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania, the group said. Jane Nabakooza, a pediatrician with Uganda's malaria control program, said she expects the government will make Coartem Baby available to patients free of charge, even after losing funding when the U.S. shrank its foreign aid program earlier this year. Some malaria funding from outside sources, including the Global Fund to Fight AIDS, Malaria and Tuberculosis, remains available for programs such as indoor spraying to kill mosquitoes that spread the malaria-causing parasite. Because of funding shortages, 'we are focusing on those that are actually prone to severe forms of malaria and malaria deaths, and these are children under 5 years,' she said.
Yahoo
8 hours ago
- Yahoo
New malaria drug for babies offers hope to health workers in Uganda
Uganda New Malaria Drug KAMPALA, Uganda (AP) — Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a miscarriage later attributed to untreated malaria in her. The Ugandan farmer said recently that she regretted the loss of what would have been her second child 'because I didn't discover malaria and treat it early.' Variations of such cases are commonly reported by Ugandan health workers who witness stillbirths or feverish babies that die within days from undiagnosed malaria. The deaths are part of a wider death toll tied to the mosquito-borne disease, the deadliest across Africa, but one easily treated in adults who seek timely medical care. Until recently, a major gap in malaria treatment was how to care for newborns and infants infected with malaria who weren't strong enough to receive regular medication. That changed last month when Swiss medical regulators approved medicine from the Basel-based pharmaceutical company Novartis for babies weighing between 2 and 5 kilograms (nearly 4½ to 11 pounds). Swissmedic said the treatment, a sweet-tasting tablet that disperses into a syrup when dropped into water, was approved in coordination with the World Health Organization under a fast-track authorization process to help developing countries access much-needed treatment. Africa's 1.5 billion people accounted for 95% of an estimated 597,000 malaria deaths worldwide in 2023, according to the WHO. More than three-quarters of those deaths were among children. In Uganda, an east African country of 45 million people, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023. Many were children younger than 5 and pregnant women, according to WHO. Nigeria, Congo and Uganda — in that order — are the African countries most burdened by malaria, a parasitic disease transmitted to humans through the bites of infected mosquitoes that thrive and breed in stagnant water. The drug approved by Swiss authorities, known as Coartem Baby in some countries and Riamet Baby in others, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including for older children. Before Coartem Baby, antimalarial drugs designed for older children were administered to small infants with careful adjustments to avoid overdose or toxicity. Ugandan authorities, who have been working to update clinical guidelines for treating malaria, say the new drug will be rolled out as soon as possible. It is not yet available in public hospitals. The development of Coartem Baby has given hope to many, with local health workers and others saying the medicine will save the lives of many infants. Ronald Serufusa, the top malaria official for the district of Wakiso, which shares a border with the Ugandan capital of Kampala, said he believes Coartem Baby will be available 'very, very soon' and that one priority is sensitizing the people adhering to treatment. Some private pharmacies already have access to Coartem Baby, 'flavored with orange or mango' to make it palatable for infants, he said. During the so-called malaria season, which coincides with rainy periods twice a year, long lines of sick patients grow outside government-run health centers across Uganda. Many are often women with babies strapped to their backs. Health workers now are trained to understand that 'malaria can be implicated among newborns,' even when other dangerous conditions like sepsis are present, Serufusa said. 'If they don't expand their investigations to also suspect malaria, then it goes unnoticed,' he said, speaking of health workers treating babies. The Malaria Consortium, a global nonprofit based in London, in a statement described the approval of Coartem Baby as 'a major leap forward for saving the lives of young children in countries affected by malaria.' In addition to Uganda, the drug will be rolled out in Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania, the group said. Jane Nabakooza, a pediatrician with Uganda's malaria control program, said she expects the government will make Coartem Baby available to patients free of charge, even after losing funding when the U.S. shrank its foreign aid program earlier this year. Some malaria funding from outside sources, including the Global Fund to Fight AIDS, Malaria and Tuberculosis, remains available for programs such as indoor spraying to kill mosquitoes that spread the malaria-causing parasite. Because of funding shortages, 'we are focusing on those that are actually prone to severe forms of malaria and malaria deaths, and these are children under 5 years,' she said. ___ The Associated Press receives financial support for global health and development coverage in Africa from the Gates Foundation. The AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at Solve the daily Crossword
Yahoo
10 hours ago
- Yahoo
Breakthrough study finds deficiency of this common nutrient could contribute to Alzheimer's
A deficiency of the metal lithium in the body could be a key factor contributing to the development of dementia in Alzherimer's patients, a groundbreaking new study reveals. The decade-long research, published in the journal Nature, shows for the first time that lithium occurs naturally in the brain and maintains the normal function of all its major cell types, preventing nerves from degradation. Scientists from Harvard Medical School found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, a similar lithium depletion accelerated memory decline. A reduced lithium level was found in some cases due to the metal's impaired uptake and its binding to amyloid plaques, which are known to be smoking gun signs of Alzheimer's. Researchers also showed that a new type of lithium compound – lithium orotate – can avoid capture by amyloid plaques and restore memory in mice. In the study, scientists used an advanced type of mass spectroscopy chemical analysis method to measure trace levels of about 30 different metals in the brain and blood samples from a range of people, including cognitively healthy people, those in an early stage of dementia, and those with advanced Alzheimer's. The analysis revealed that lithium was the only metal with markedly different levels across groups, which also seemed to change at the earliest stages of memory loss. 'Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,' study senior author Bruce Yankner said. 'It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug,' Dr Yankner said. Although lithium compounds have been historically in use to treat a range of mental conditions like bipolar disorder and major depressive disorder, in these cases, they are given at much higher concentrations that could even be toxic to older people. Scientists have now found that lithium orotate is effective at one-thousandth this dose – enough to mimic the natural level of lithium in the brain. The latest findings with lithium orotate, however, needs to be confirmed in humans via clinical trials. Yet, researchers suspect that measuring lithium levels could help screen people for early Alzheimer's. The findings revise the theory of Alzheimer's disease, which affects nearly 400 million people worldwide, offering a new strategy for early diagnosis, prevention, and treatment. Decades of studies have shown that Alzheimer's disease involves an array of brain abnormalities, including clumps of the protein amyloid beta, tangles of the protein tau, and a loss of the brain's protective protein REST. However, these abnormalities have never fully explained the condition. For instance, it remains unclear why some people with Alzheimer's-like changes in the brain never go on to develop dementia or cognitive decline. Recent treatments developed to target amyloid beta plaques also don't seem to reverse memory loss, only modestly reducing the rate of cognitive decline. Now, scientists say lithium could be the critical missing link. 'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' Dr Yankner said. 'You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial... But so far the results are very encouraging,' he added. Solve the daily Crossword
